Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia

I. J. Abbott; A. W.J. Jenney; C. J. Jeremiah; M. Mirčeta; J. P. Kandiah; D. C. Holt; S. Y.C. Tong; D. W. Spelman

doi:10.1128/AAC.02015-15

Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia

I. J. Abbott, A. W.J. Jenney, C. J. Jeremiah, M. Mirčeta, J. P. Kandiah, D. C. Holt, S. Y.C. Tong, D. W. Spelman

Research output: Contribution to journal › Article › Research › peer-review

10 Citations (Scopus)

Abstract

A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

Original language	English
Pages (from-to)	7837-7841
Number of pages	5
Journal	Antimicrobial Agents and Chemotherapy
Volume	59
Issue number	12
DOIs	https://doi.org/10.1128/AAC.02015-15
Publication status	Published - 1 Dec 2015
Externally published	Yes

Access to Document

10.1128/AAC.02015-15

285718613-oaFinal published version, 411 KB

Link to publication in Scopus

Cite this

Abbott, I. J., Jenney, A. W. J., Jeremiah, C. J., Mirčeta, M., Kandiah, J. P., Holt, D. C., Tong, S. Y. C., & Spelman, D. W. (2015). Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia. Antimicrobial Agents and Chemotherapy, 59(12), 7837-7841. https://doi.org/10.1128/AAC.02015-15

@article{861c914ac91a4fd2bf275c899fd890a6,

title = "Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia",

abstract = "A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioM{\'e}rieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.",

author = "Abbott, {I. J.} and Jenney, {A. W.J.} and Jeremiah, {C. J.} and M. Mir{\v c}eta and Kandiah, {J. P.} and Holt, {D. C.} and Tong, {S. Y.C.} and Spelman, {D. W.}",

year = "2015",

month = dec,

day = "1",

doi = "10.1128/AAC.02015-15",

language = "English",

volume = "59",

pages = "7837--7841",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "1098-6596",

publisher = "American Society for Microbiology",

number = "12",

}

Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia. / Abbott, I. J.; Jenney, A. W.J.; Jeremiah, C. J.; Mirčeta, M.; Kandiah, J. P.; Holt, D. C.; Tong, S. Y.C.; Spelman, D. W.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 12, 01.12.2015, p. 7837-7841.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Reduced in vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia

AU - Abbott, I. J.

AU - Jenney, A. W.J.

AU - Jeremiah, C. J.

AU - Mirčeta, M.

AU - Kandiah, J. P.

AU - Holt, D. C.

AU - Tong, S. Y.C.

AU - Spelman, D. W.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

AB - A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, > 1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P<0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

UR - http://www.scopus.com/inward/record.url?scp=84954475513&partnerID=8YFLogxK

U2 - 10.1128/AAC.02015-15

DO - 10.1128/AAC.02015-15

M3 - Article

C2 - 26392488

AN - SCOPUS:84954475513

VL - 59

SP - 7837

EP - 7841

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 12

ER -